{"id":745571,"date":"2017-04-10T15:30:00","date_gmt":"2017-04-10T15:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/dr-john-h-noseworthy-nominated-to-stand-for-election-to-merck-board-of-directors\/"},"modified":"2025-11-07T01:26:35","modified_gmt":"2025-11-07T06:26:35","slug":"dr-john-h-noseworthy-nominated-to-stand-for-election-to-merck-board-of-directors","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/dr-john-h-noseworthy-nominated-to-stand-for-election-to-merck-board-of-directors\/","title":{"rendered":"Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors"},"content":{"rendered":"<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that Dr. John H. Noseworthy, president and chief<br \/>\n      executive officer of Mayo Clinic, has been nominated to stand for<br \/>\n      election to the company\u2019s board of directors. The annual election of Dr.<br \/>\n      Noseworthy and the other directors will take place in connection with<br \/>\n      Merck\u2019s Annual Meeting of Shareholders on May 23, 2017. With the<br \/>\n      proposed addition of Dr. Noseworthy, and the planned retirement of C.<br \/>\n      Robert Kidder, the Merck board will include 13 members.\n    <\/p>\n<p>\n      \u201cWe are pleased to nominate Dr. John Noseworthy to stand for election to<br \/>\n      the Merck board and look forward to benefiting from his first-hand<br \/>\n      insights about patient care and health care delivery as a leader of one<br \/>\n      of the largest non-profit health systems in the United States,\u201d said<br \/>\n      Kenneth C. Frazier, chairman and chief executive officer, Merck.\n    <\/p>\n<p>\n      Dr. John H. Noseworthy is president and chief executive officer of Mayo<br \/>\n      Clinic, a not-for-profit organization operating in five states that is<br \/>\n      dedicated to medical care, research and education. Prior to his current<br \/>\n      appointment, he served as chair of Mayo Clinic\u2019s Department of<br \/>\n      Neurology, medical director of the Department of Development, and vice<br \/>\n      chair of the Mayo Clinic Rochester Executive Board. Dr. Noseworthy is a<br \/>\n      professor in the Department of Neurology and served as editor-in-chief<br \/>\n      for <i>Neurology<\/i>, the official journal of the American Academy of<br \/>\n      Neurology.\n    <\/p>\n<p>\n      Dr. Noseworthy earned his medical degree from Dalhousie University in<br \/>\n      Halifax, Nova Scotia, Canada. He completed his neurology training at<br \/>\n      Dalhousie University and the University of Western Ontario, and a<br \/>\n      research fellowship at Harvard Medical School. He has received the<br \/>\n      Alumnus of the Year award from Dalhousie University, an honorary<br \/>\n      doctorate of science degree from the University of Western Ontario, and<br \/>\n      an honorary doctorate of laws from Dalhousie University. He also is a<br \/>\n      Health Governor of the World Economic Forum.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For over a century, Merck has been a global health care leader working<br \/>\n      to help the world be well. Merck is known as MSD outside the United<br \/>\n      States and Canada. Through our prescription medicines, vaccines,<br \/>\n      biologic therapies, and animal health products, we work with customers<br \/>\n      and operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51538732&amp;newsitemid=20170410006137&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=47f111d672c09d7b422493c71632cc2c\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51538732&amp;newsitemid=20170410006137&amp;lan=en-US&amp;anchor=Twitter&amp;index=2&amp;md5=d7fe580207181adde65bf36cef5f6f02\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51538732&amp;newsitemid=20170410006137&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=597132f7d6fe08aa97301bde727e3c64\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51538732&amp;newsitemid=20170410006137&amp;lan=en-US&amp;anchor=YouTube&amp;index=4&amp;md5=0b0ea80fde25fef3193717a1b2347412\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51538732&amp;newsitemid=20170410006137&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=c1640dd9b4cd57e59c0d3827bedcb9a0\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. If underlying assumptions prove<br \/>\n      inaccurate or risks or uncertainties materialize, actual results may<br \/>\n      differ materially from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2016 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51538732&amp;newsitemid=20170410006137&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=6&amp;md5=a945af91a49758ef268dd48af516ccac\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20170410006137r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><br \/>\n<span class=\"bwct31415\" \/><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Tracy Ogden, 215-370-5597<br \/>or<br \/>Investors:<br \/>Teri        Loxam, 908-740-1986     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Dr. John H. Noseworthy, president and chief executive officer of Mayo Clinic, has been nominated to stand for election to the company\u2019s board of directors. The annual election of Dr. Noseworthy and the other directors will take place in connection with Merck\u2019s Annual Meeting of Shareholders on May 23, 2017. With the proposed addition of Dr. Noseworthy, and the planned retirement of C. Robert Kidder, the Merck board will include 13 members. \u201cWe are pleased to nominate Dr. John Noseworthy to stand for election to the Merck board and look forward to benefiting from his first-hand insights about patient care and health care delivery as a leader of one of the largest non-profit health systems in the United States,\u201d said Kenneth C. Frazier, chairman and chief executive officer, Merck. Dr. John H. Noseworthy is president and chief executive officer of Mayo Clinic, a not-for-profit organization<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-745571","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/dr-john-h-noseworthy-nominated-to-stand-for-election-to-merck-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Dr. John H. Noseworthy, president and chief executive officer of Mayo Clinic, has been nominated to stand for election to the company\u2019s board of directors. The annual election of Dr. Noseworthy and the other directors will take place in connection with Merck\u2019s Annual Meeting of Shareholders on May 23, 2017. With the proposed addition of Dr. Noseworthy, and the planned retirement of C. Robert Kidder, the Merck board will include 13 members. \u201cWe are pleased to nominate Dr. John Noseworthy to stand for election to the Merck board and look forward to benefiting from his first-hand insights about patient care and health care delivery as a leader of one of the largest non-profit health systems in the United States,\u201d said Kenneth C. Frazier, chairman and chief executive officer, Merck. Dr. John H. Noseworthy is president and chief executive officer of Mayo Clinic, a not-for-profit organization\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/dr-john-h-noseworthy-nominated-to-stand-for-election-to-merck-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/dr-john-h-noseworthy-nominated-to-stand-for-election-to-merck-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/dr-john-h-noseworthy-nominated-to-stand-for-election-to-merck-board-of-directors\\\/\",\"name\":\"Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2017-04-10T15:30:00+00:00\",\"dateModified\":\"2025-11-07T06:26:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/dr-john-h-noseworthy-nominated-to-stand-for-election-to-merck-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/dr-john-h-noseworthy-nominated-to-stand-for-election-to-merck-board-of-directors\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/dr-john-h-noseworthy-nominated-to-stand-for-election-to-merck-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/dr-john-h-noseworthy-nominated-to-stand-for-election-to-merck-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Dr. John H. Noseworthy, president and chief executive officer of Mayo Clinic, has been nominated to stand for election to the company\u2019s board of directors. The annual election of Dr. Noseworthy and the other directors will take place in connection with Merck\u2019s Annual Meeting of Shareholders on May 23, 2017. With the proposed addition of Dr. Noseworthy, and the planned retirement of C. Robert Kidder, the Merck board will include 13 members. \u201cWe are pleased to nominate Dr. John Noseworthy to stand for election to the Merck board and look forward to benefiting from his first-hand insights about patient care and health care delivery as a leader of one of the largest non-profit health systems in the United States,\u201d said Kenneth C. Frazier, chairman and chief executive officer, Merck. Dr. John H. Noseworthy is president and chief executive officer of Mayo Clinic, a not-for-profit organization","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/dr-john-h-noseworthy-nominated-to-stand-for-election-to-merck-board-of-directors\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:35+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/dr-john-h-noseworthy-nominated-to-stand-for-election-to-merck-board-of-directors\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/dr-john-h-noseworthy-nominated-to-stand-for-election-to-merck-board-of-directors\/","name":"Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2017-04-10T15:30:00+00:00","dateModified":"2025-11-07T06:26:35+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/dr-john-h-noseworthy-nominated-to-stand-for-election-to-merck-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/dr-john-h-noseworthy-nominated-to-stand-for-election-to-merck-board-of-directors\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/dr-john-h-noseworthy-nominated-to-stand-for-election-to-merck-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"71bcc925-d3e1-4dfa-b029-6abd72911c70","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745571","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745571\/revisions"}],"predecessor-version":[{"id":3674935,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745571\/revisions\/3674935"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745571"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745571"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}